Crinetics Pharmaceuticals Free Cash Flow (FCF) History (CRNX)

Crinetics Pharmaceuticals reported −$383.7M in free cash flow for fiscal 2025, a decrease of $149.6M from the previous fiscal year, with a free cash flow margin of −4985.50%.

View full Crinetics Pharmaceuticals company overview

Crinetics Pharmaceuticals free cash flow by year

Crinetics Pharmaceuticals annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20252025-12-31−$383.7M−$149.6M−4985.50%
20242024-12-31−$234.0M−$60.8M−22525.31%
20232023-12-31−$173.3M−$56.4M−4318.12%
20222022-12-31−$116.9M−$27.8M
20212021-12-31−$89.0M−$26.8M
20202020-12-31−$62.2M−$15.3M−87623.94%
20192019-12-31−$46.9M−$26.4M−3929.00%
20182018-12-31−$20.5M−$10.7M−845.06%
20172017-12-31−$9.8M−$4.1M−478.39%
20162016-12-31−$5.7M−960.61%

Crinetics Pharmaceuticals free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from −$62.2M to −$383.7M, a net decrease of $321.5M. Crinetics Pharmaceuticals's latest reported quarter, Q2 2026, generated −$94.7M in free cash flow, a decrease of $5.7M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Crinetics Pharmaceuticals filings at SEC.gov ↗